How to appeal a Blue Cross Blue Shield of Massachusetts inflammatory bowel disease (crohn's + uc) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Massachusetts-specific note: Non-profit; ~3M members. MA has the most expansive state mandated benefits in the US and strong supplemental parity rules. MA OPP (Office of Patient Protection) provides external review separately from carriers — distinct from federal IRO process for fully-insured plans.

What Blue Cross Blue Shield of Massachusetts's policy requires for inflammatory bowel disease (crohn's + uc)

Cited policy: BCBS Rinvoq (Upadacitinib) for UC + Crohn's PA

Moderate-severe UC (FDA Mar 2022) or CD (FDA May 2023). Failure or intolerance of >=1 anti-TNF OR contraindication. Induction 45 mg PO daily x 8 wk (UC) or 12 wk (CD), then 15 mg or 30 mg maintenance. TB / HBV / HCV / lipids / CBC screening required. Boxed-warning risk discussion documented.

How Blue Cross Blue Shield of Massachusetts denies inflammatory bowel disease (crohn's + uc) — and how to counter it

Where Blue Cross Blue Shield of Massachusetts pushes back: 1) JAK boxed warning — must fail 2 biologics first; 2) Patient >50 — denied per ORAL-Surveillance; 3) Must try Stelara/Entyvio before JAK.

Counter-arguments that hold up: Rinvoq UC FDA Mar 16, 2022 (U-ACHIEVE + U-ACCOMPLISH Danese Lancet 2022); Rinvoq CD FDA May 18, 2023 (U-EXCEED + U-EXCEL Loftus NEJM 2023). ORAL-Surveillance (Ytterberg NEJM 2022;386:316) was a POST-MARKETING RA cohort >=50 with >=1 CV risk factor — NOT IBD; class boxed warning is patient-specific. AGA UC 2020 + CD 2020 list JAK as parallel option after TNFi failure (or alternative if TNFi contraindicated). Document patient-specific CV / malignancy / VTE risk vs benefit.

What Blue Cross Blue Shield of Massachusetts typically denies for inflammatory bowel disease (crohn's + uc)

Across Blue Cross Blue Shield of Massachusetts's commercial and Medicare books, denials cluster around a small number of patterns. For inflammatory bowel disease (crohn's + uc), expect:

• MA-specific mandated benefit disputes (most generous in US)
• Behavioral health parity (MA has tighter parity rules than federal MHPAEA)
• Tiered-network provider disputes
• Specialty drug PA

Treatments most often denied in this category

These are the inflammatory bowel disease (crohn's + uc) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira (adalimumab)
• Remicade (infliximab)
• Cimzia (CD only)
• Simponi (UC only)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)

How to submit the appeal to Blue Cross Blue Shield of Massachusetts

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Massachusetts cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Massachusetts's portal (members: https://home.bluecrossma.com ; providers: https://provider.bluecrossma.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Massachusetts's prior-authorization criteria by drug: Blue Cross Blue Shield of Massachusetts PA criteria on ApprovalHelp.